Brain Changes With a GLP-1 Drug for Obesity in Youth and Adults
Tests semaglutide against placebo in people with obesity, comparing brain and appetite changes.
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Aurora, United StatesSee the site
- Trial code
- Registry title
- Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 120 people, planned
- Started
- 15 Jun 2026
- Expected to end
- 30 Apr 2031
- Type of study
- Interventional, 6 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Semaglutide 1.7mg subcutaneous
- Placebo
- Record updated
- 2 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers aged 12-18 and adults aged 30-45 who are living with obesity. It studies how a GLP-1 drug affects the brain, appetite and eating.
- Age
- 12 to 18 years, or 30 to 45 years
- Sex
- Males and females (sex assigned at birth)
- Disease stage
- Obesity: for 12-18 years, BMI above 120% of the 95th percentile; for 30-45 years, BMI above 35 kg/m2
- Earlier treatment
- No GLP-1 drug for weight management (for example exenatide, liraglutide, semaglutide, tirzepatide) in the last 3 months. Antidepressants are accepted; anti-psychotic medicines are not.
Main reasons for not taking part
- Type 2 diabetes
- Current or past anorexia nervosa, or current bulimia nervosa
- Neurological disorder or stroke history
- Cannot have an MRI scan (for example, braces)
- Pregnant, breastfeeding, or wanting to become pregnant
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- English-speaking
- male or female (sex assigned at birth)
- 12-18 y/o with obesity (BMI>120% of the 95th %ile)
- 30-45 y/o with obesity (BMI>35 kg/m2)
Who cannot take part
- treated with glucagon-like peptide-1 (GLP-1) agonists (e.g., exenatide, liraglutide, semaglutide, tirzepatide) for weight management in the prior 3 months
- currently taking anti-psychotic medications (anti-depressants accepted)
- any contraindication to receiving a MRI (e.g., orthodontal braces)
- diagnosis of type 2 diabetes
- neurological disorder (e.g., Parkinson's disease) or history of stroke
- psychological/behavioral dysfunction (e.g., autism spectrum disorder) or physical impairment that would interfere with study procedures, as determined by study physician
- current or lifetime anorexia nervosa or current bulimia nervosa
- head injury resulting in loss of consciousness >30min
- if female, desiring to become pregnant, or currently pregnant or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 45 years old?
Where in United States
- University of Colorado Anschutz Medical CampusAurora, United StatesContact: Allison Shapiro, PhD, MPHNot yet recruiting
About the trial
What the trial wants to find out
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.
The 6 groups in the trial
- Pubertal Adolescent - Continuous TreatmentTreatment being tested
Pubertal adolescents defined as Tanner stage 2-4 and/or 12-15 y/o who will receive 32 weeks of semaglutide (s.c.)
Treatment: Semaglutide 1.7mg subcutaneous
- Pubertal Adolescent - Early Treatment CessationTreatment being tested
Pubertal adolescents defined as Tanner stage 2-4 and/or 12-15 y/o who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo
Treatment: Semaglutide 1.7mg subcutaneous and Placebo
- Post-Pubertal Adolescent - Continuous TreatmentTreatment being tested
Post-pubertal adolescents defined as Tanner stage 5 and/or 16-18 y/o who will receive 32 weeks of semaglutide (s.c.)
Treatment: Semaglutide 1.7mg subcutaneous
- Post-Pubertal Adolescent - Early Treatment CessationTreatment being tested
Post-pubertal adolescents defined as Tanner stage 5 and/or 16-18 y/o who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo
Treatment: Semaglutide 1.7mg subcutaneous and Placebo
- Adult - Continuous TreatmentExisting treatment, for comparison
Adults defined as 30-45 y/o who will receive 32 weeks of semaglutide (s.c.)
Treatment: Semaglutide 1.7mg subcutaneous
- Adult - Early Treatment CessationExisting treatment, for comparison
Adults defined as 30-45 y/o who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo
Treatment: Semaglutide 1.7mg subcutaneous and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial
- Plain-language title
- Brain Changes With a GLP-1 Drug for Obesity in Youth and AdultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07021937, who can take part
- Record updated
- 2 July 2026